[Detection of sedative effect by electronystagmography].
D000661:Amphetamine / Q000494:pharmacology*; D000959:Antihypertensive Agents / Q000494:pharmacology*; D002110:Caffeine / Q000494:pharmacology*; D002746:Chlorpromazine / Q000494:pharmacology; D003984:Dibenzazepines / Q000494:pharmacology; D004558:Electric Stimulation; D006801:Humans; D006993:Hypnotics and Sedatives / Q000037:antagonists & inhibitors / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology*; D008722:Methods; D010424:Pentobarbital / Q000494:pharmacology; D010633:Phenmetrazine / Q000494:pharmacology; D010640:Phenothiazines / Q000494:pharmacology*; D010672:Phenytoin / Q000494:pharmacology*; D011398:Promethazine / Q000494:pharmacology; D013847:Thiethylperazine / Q000494:pharmacology; D014724:Vestibular Function Tests
D000959:Antihypertensive Agents; D003984:Dibenzazepines; D006993:Hypnotics and Sedatives; D007093:Imidazoles; D010640:Phenothiazines; D002110:Caffeine; D010672:Phenytoin; D013847:Thiethylperazine; D000661:Amphetamine; D011398:Promethazine; D010424:Pentobarbital; D002746:Chlorpromazine; D010633:Phenmetrazine
Der Nachweis sedativer Wirkungen durch die Elektronystagmographie.